24% revenue growth, profit margin expansion, and profitability
Just what the doctor ordered!
Could we se a 100% gain today after such a beating or is it gradually going to come.
Analysts peg this years revenue growth rate around 20% and next year in the lower double digits with profitability. I'm not so sure EDAP will stay down for too much longer. I'm looking forward to Friday and will add to my position on a positive release. I think the FDA sell off is well overdone and created an opportunity. The overall revenue and path to profitability of the company is quite attractive for a multibagger from this price. HIFU is only in the infancy of all of its growth applications.
Yahoo may go ahead and destroy my post but the point is that the company is in a growth trend and Focal One sales are starting to accelerate and revenues are growing. The company took a hit like FDA approval is the end all be all but really it is just an addition. From the last call this coming release could be good and we expect to hear more about the next FDA step.
Foc#$%$l One s#$%$les #$%$re #$%$cceler#$%$ting. There is once #$%$g#$%$in d#$%$ylight on FDA #$%$pprov#$%$l in the US. EDAP stock should tr#$%$de subst#$%$nti#$%$lly up #$%$fter #$%$ different picture is p#$%$inted Frid#$%$y. MSON is the HIFU comp#$%$rison on W#$%$ll Street #$%$nd they h#$%$ve h#$%$d #$%$ sweet ride this ye#$%$r le#$%$ving more room for upside here on #$%$ny success.
This has happened before. The earnings this quarter are expected to be good and we have been enlightened that Albatherm is not dead in the US waters. Don't be surprised to see volume jump 5 fold and the price to go up substantially any day now. Someone runs this stock on the bull side and the day is coming soon... Focal One is a very nice machine and sales are accelerating.
The company projects 200 million in revenues with a good profit margin within 4-6 years. If the team does what they say they will ADEP will hit 50 bucks a share or more and have a few bucks in earnings per share.
Personal incomes rose 8% in the US. Much more money is available for looks. ELOS will likely be in the high double digits next year at this time. The CYNO report was very nice showing a healthy market.
The company will be taken over very shortly. The US market has been the only laggard and that is picking up now. 2015 will be a great year as a push to on-shoring with US companies persists. Take the dip to where we are as a gift we should soon see double digits again.
Its already starting this year. Go pick another technology that is not commercial to use that argument on. HYGS will likely be at a new post reverse split high sometime within a year,
Lets hope Ebola does not hit hard at home but it is a wake up call. All hospitals need to have the resources available just in case isolation occurs. Wallets should open up once again and revenues should turn up substantially in the coming quarters. It might not be the the next one since the US scare had yet to occur for the most of it.
AHPI gets a large portion of the respirator revenue worldwide. Every time an Ebola patient is moved respirators are necessary in the US. I am assuming the US will support using the same procedure in West Africa as the disease is combated there. Many people will be moved as new fever centers are built. There are many avenues AHPI will increase revenues as we attack Ebola back. Lets hope nobody on that flight Monday contracts Ebola or all hell will break loose in the US as those travelers went nationwide.
We already passed that point with VICL and their Ebola vaccine. Serepta is adding about Vical's entire market cap to theirs on that news. What happens when Vical reopens their study? It is necessary that government resources are thrown at all companies working or have worked on a vaccine.
Don't buy VICL for Ebola. Buy it for the ability to target any virus and its ability to help manufacture a vaccine of another company when proven successful. The study was halted when there were limited Ebola patients to treat.
Who knows how bad Ebola will get and what is coming at us next. Funding will be coming and those holding through the news could get a multibagger out of little Vical.
Vaccine Stocks should have a good run since we are seeing how much need is out there. Vical is a super buy here.
Dengue Fever is spreading much quicker this year than ever an Vical is working on a vaccine. Don't be surprised if the NHI reinstates their Vical Ebola Vaccine and helps cover the bill. Ebola starts in poor third world countries and anyone working on a vaccine was in it for the goodness of their heart. There has been a change of heart due to necessity and why start from scratch when Phase 1 was complete with Vical. Expect an announcement any time. We need as many tools as possible to battle Ebola.
type in infrared thermometer and find how many companies sell them for around thirty bucks. Almost a hundred is not a big deal
sold 100 to target ebola. Are they 50 bucks each... so like 5000 buck of revenue towards bola for a company facing trouble paying creditors a million bucks?